- 专利标题: Solid Forms of 2-((4-((S)-2-(5-Chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 1,3-Dihydroxy-2-(hydroxymethyl)propan-2-amine Salt
-
申请号: US17782478申请日: 2020-12-07
-
公开(公告)号: US20230045419A1公开(公告)日: 2023-02-09
- 发明人: Gary E. Aspnes , Scott W. Bagley , Wesley Dewitt Clark , John M. Curto , David James Edmonds , Mark E. Flanagan , Kentaro Futatsugi , David Andrew Griffith , Kim Huard , Yajing Lian , Chris Limberakis , Allyn T. Londregan , Alan M. Mathiowetz , David Walter Piotrowski , Roger B. Ruggeri
- 申请人: Pfizer Inc.
- 申请人地址: US NY New York
- 专利权人: Pfizer Inc.
- 当前专利权人: Pfizer Inc.
- 当前专利权人地址: US NY New York
- 国际申请: PCT/IB2020/061585 WO 20201207
- 主分类号: C07D405/14
- IPC分类号: C07D405/14
摘要:
The invention provides solid forms of 2-((4-((S)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((S)-oxetan-2-yl)methyl)-1H-benzo[d]imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt for example, a hydrate (e.g. a monohydrate) crystalline form (e.g. Form 2 or Form 3) or an amorphous form; as well as pharmaceutical compositions, and the uses thereof in treating diseases, conditions or disorders modulated by GLP-1R in a mammal, such as a human.
信息查询